In summary, we constructed a novel risk model based on six DNL-related genes (G6PD, LCAT, SERPINE1, SOAT2, CYP2C9, and UGT1A10) that demonstrates robust performance in prognostic stratification, immune cell infiltration, and immunotherapy response prediction in HCC patients. This evidence concerns the gene CYP2C9 and hepatocellular carcinoma.